drugset / Trial / NCT04240457

Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions

NCT04240457 ↗

Phase 2 Terminated 11 enrolled Arbor Center for Eye Care
RandomizedSequentialSingle-blindTreatment

Summary

To evaluate the safety and effectiveness of the PXL Platinum 330 device for performing Corneal Crosslinking in patients with corneal thinning conditions.

Timeline

Start
2020-07-08
Primary completion
2023-02-18
Completion
2023-02-18

Outcome

Outcome not reported

Stopped (Enrollment): “Study was terminated due to enrollment and other challenges attributable to the Covid-19 public health emergency.”

Drugs

EvaluationDrugModalityDoseRoute
Background Riboflavin Other / unclassified — —